Brokerages Expect Cellectis SA (NASDAQ:CLLS) Will Post Quarterly Sales of $3.87 Million

Wall Street brokerages predict that Cellectis SA (NASDAQ:CLLS) will announce $3.87 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Cellectis’ earnings. The highest sales estimate is $5.50 million and the lowest is $2.23 million. Cellectis reported sales of $3.08 million during the same quarter last year, which indicates a positive year over year growth rate of 25.6%. The company is expected to issue its next quarterly earnings results on Monday, March 9th.

On average, analysts expect that Cellectis will report full-year sales of $18.43 million for the current financial year, with estimates ranging from $14.40 million to $22.10 million. For the next financial year, analysts expect that the business will report sales of $60.73 million, with estimates ranging from $15.00 million to $85.20 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Cellectis.

A number of research firms have recently commented on CLLS. BidaskClub upgraded Cellectis from a “hold” rating to a “buy” rating in a research note on Thursday, December 5th. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $28.80.

Institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its stake in shares of Cellectis by 22.1% in the third quarter. Envestnet Asset Management Inc. now owns 50,228 shares of the biotechnology company’s stock worth $522,000 after purchasing an additional 9,088 shares during the period. A.R.T. Advisors LLC bought a new position in Cellectis during the second quarter valued at about $171,000. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Cellectis by 8.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company’s stock valued at $13,669,000 after acquiring an additional 104,276 shares during the period. Morgan Stanley increased its stake in Cellectis by 56.6% during the second quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock valued at $7,719,000 after acquiring an additional 178,865 shares during the period. Finally, Nikko Asset Management Americas Inc. increased its stake in Cellectis by 7.3% during the third quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company’s stock valued at $13,669,000 after acquiring an additional 89,961 shares during the period. Institutional investors and hedge funds own 30.97% of the company’s stock.

Shares of Cellectis stock traded down $0.03 during trading on Tuesday, reaching $15.95. The company’s stock had a trading volume of 103,026 shares, compared to its average volume of 117,632. The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.93 and a current ratio of 7.99. The business’s fifty day moving average price is $13.24 and its 200-day moving average price is $13.43. The firm has a market cap of $677.08 million, a price-to-earnings ratio of -8.26 and a beta of 1.82. Cellectis has a one year low of $9.50 and a one year high of $20.84.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Read More: What is the formula for calculating total return?

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.